Dec 20, 2004 by Charly TraversMore Trouble at Big PharmaThis lung cancer drug is not as effective as once hoped.
Dec 14, 2004 by Charly TraversA Stagnant Drug StockA drug launch is not driving share price increases for Indevus.
Dec 13, 2004 by Charly TraversPDL Rakes It InA robust revenue stream combined with an exciting drug pipeline is the recipe for success.
Dec 7, 2004 by Charly TraversSpin the Medicine BottleIs a new MS drug going to be a top seller or a bottom-dweller? Here's how to find out.
Dec 3, 2004 by Charly TraversSex Patch Returns to LabFDA panel's safety concerns have sidetracked P&Gs Intrinsa.
Nov 23, 2004 by Charly TraversDon't Be Afraid of BiotechYou don't need to be a scientist to invest in this high-growth sector.
Nov 23, 2004 by Charly TraversMylan's "Three-Ring Circus"Icahn is involved in the Mylan-King Pharmaceuticals deal for his benefit only.
Nov 19, 2004 by Charly TraversA New Drug for Lung CancerGenentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer.
Nov 18, 2004 by Charly TraversA Glimpse of Bristol-Myers' PortfolioLate-stage drugs are crucial for a company beset with patent losses.
Nov 16, 2004 by Charly TraversFinding Biotech's 50-BaggersUncovering tomorrow's industry leaders today.
Nov 9, 2004 by Charly TraversAre Stem Cells a Rule Breaker?Does the science offer real hope or just hype?
Nov 9, 2004 by Charly TraversGenta's on the RopesAventis' exit leaves the pharmaceutical company in dire straits.
Nov 4, 2004 by Charly TraversDrug Growth Screeching to a HaltGeneric-drug threats can quickly erode sales.
Nov 2, 2004 by Charly TraversJust the Medicine for PDLLosses are shrinking as drug royalties spur strong revenue growth.
